Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

EpitalonGHK-CuThymulinThymosin α1

Dimension	Epitalon Epithalon	GHK-Cu Copper Tripeptide-1	Thymulin FTS	Thymosin α1 Zadaxin
Evidence tier	CPreclinical only	BHuman observational	CPreclinical only	AHuman RCT evidence
Intelligence Score™	3.9/ 10 · Emerging	5.2/ 10 · Emerging	3.7/ 10 · Emerging	6.4/ 10 · Moderate
Family	Pineal tetrapeptide	Copper-binding tripeptide	Zinc-dependent thymic peptide	Thymic peptide (28-aa)
Half-life	Short	Short (minutes, plasma)	Short	~2 h
Typical dose	5–10 mg/day for 10–20 days, cyclic	1–2 mg/day (anecdotal, injectable)	Experimental	1.6 mg, 2× weekly
Routes	Subcutaneous	Topical, Subcutaneous	Subcutaneous	Subcutaneous
Tier label	Preclinical only	Human observational	Preclinical only	Human RCT
Mechanism	Reported telomerase activation in cell culture; pineal axis modulation.	Modulates wound-healing gene expression; binds copper(II) with high affinity.	Zinc-dependent modulation of T-cell differentiation.	Modulates T-cell maturation and innate immunity via TLR signalling.
Reported uses	recovery-sleep	recovery-sleep	—	—
Contraindications	— Pregnancy — Active malignancy (theoretical)	— Wilson's disease — Copper sensitivity	— No human safety data	— Active organ transplant (caution — immunostimulation)
Citations	1	1	1	1

CPreclinical only

Intelligence Score™: 3.9/ 10 · Emerging
Family: Pineal tetrapeptide
Half-life: Short
Typical dose: 5–10 mg/day for 10–20 days, cyclic
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: Reported telomerase activation in cell culture; pineal axis modulation.
Reported uses: recovery-sleep
Contraindications: — Pregnancy
— Active malignancy (theoretical)
Citations: 1

BHuman observational

Intelligence Score™: 5.2/ 10 · Emerging
Family: Copper-binding tripeptide
Half-life: Short (minutes, plasma)
Typical dose: 1–2 mg/day (anecdotal, injectable)
Routes: Topical, Subcutaneous
Tier label: Human observational
Mechanism: Modulates wound-healing gene expression; binds copper(II) with high affinity.
Reported uses: recovery-sleep
Contraindications: — Wilson's disease
— Copper sensitivity
Citations: 1

CPreclinical only

AHuman RCT evidence

Intelligence Score™: 6.4/ 10 · Moderate
Family: Thymic peptide (28-aa)
Half-life: ~2 h
Typical dose: 1.6 mg, 2× weekly
Routes: Subcutaneous
Tier label: Human RCT
Mechanism: Modulates T-cell maturation and innate immunity via TLR signalling.
Reported uses: —
Contraindications: — Active organ transplant (caution — immunostimulation)
Citations: 1

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.